Tirzepatide ���子背景与靶点 — 2026 Update

By Editorial Desk · published 2026-03-29 · last reviewed 2026-05-19 · Topic

The short version of dual agonist fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-05-19. Anything still debated is marked as such rather than presented as settled.

Tirzepatide 分子背景与靶点

当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。

Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。

在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。

Molecular Basis and Receptor Pharmacology

At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.

An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.

Tirzepatide at a glance

Background And Receptor Mechanism

Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.

Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.

Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.

Related pages on this site

• Verified report
• Balanced index
• Adaptive comparison
• Comprehensive workbook
• Automated archive
• Efficient dataset
• Lightweight workbook
• Measured review

Handling, Storage, and Analytical Methods

Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.

Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.

Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.

储存处理与检测方法

溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。

定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。

Supporting material

Science and Health expanded on Eddy's view that sickness was a mental error. People said that simply reading Science and Health had healed them; cures were claimed for everything from cancer to blindness. Eddy wrote in the New York Sun in December 1898, in an article called "To the Christian World," that she had personally healed tuberculosis, diphtheria and "at one visit a cancer that had eaten the flesh of the neck and exposed the jugular vein so that it stood out like a cord. I have physically restored sight to the blind, hearing to the deaf, speech to the dumb, and have made the lame walk." Eddy wrote that her views had derived, in part, from having witnessed the apparent recovery of patients she had treated with homeopathic remedies so diluted they were drinking plain water. She concluded that Divine Mind was the healer:

=== 1. CAL vs. Pseudopocket === Clinical attachment loss refers to the loss of periodontal attachment due to apical migration of the junctional epithelium (JE), accompanied by destruction of gingival connective tissue fibers and periodontal ligament fibers. This results in the formation of a true periodontal pocket, where the base of the pocket lies apical to the cementoenamel junction (CEJ). CAL develops through a complex host–microbial interaction, beginning with microbial dysbiosis, commonly involving anaerobic pathogens such as Porphyromonas gingivalis. This dysbiotic biofilm triggers an exaggerated host immune response, characterized by neutrophil infiltration, pro-inflammatory cytokine release, and complement activation. With chronic inflammation, destructive enzymes such as matrix metalloproteinases are activated, leading to the breakdown of gingival connective tissue fibers and detachment from the cementum. This allows the JE to migrate apically, deepening the periodontal pocket and facilitating further bacterial invasion. Simultaneously, inflammatory mediators stimulate RANKL-mediated osteoclast activation, resulting in alveolar bone resorption. Biologically, this process is irreversible, involving permanent breakdown of the JE, connective tissue fibers, periodontal ligament, and supporting bone. Clinically, CAL is the gold standard for diagnosing periodontitis and marks the transition from gingivitis to established periodontal disease. In contrast, a pseudopocket is characterized by increased probing depth without attachment loss.

Euromac, an EU-funded consortium of medical and research institutes across Europe which is building a patient registry and raising standards of care for people with McArdle Disease. Archived 2021-04-22 at the Wayback Machine International Association for Muscle Glycogen Storage Disease (IamGSD). Walking With McArdle's - IamGSD videos EUROMAC Introduction - Video about McArdle disease and the EUROMAC Registry of McArdle disease and other rare glycogenoses patients

As a result of tight advertising and marketing prohibitions, tobacco companies view packaging as a vital factor in displaying brand imagery and creating in-store presence at the point of purchase. Market testing shows the influence of this dimension in shifting the consumer's choice when the same product is displayed in alternative packaging. Companies have manipulated a variety of elements on packaging designs to communicate the impression of lower tar content or milder cigarettes, although the actual contents were the same. Some countries require cigarette packs to display warnings about the health impact of smoking. The United States was the first, later followed by other countries including Canada, most of Europe, the United Kingdom, Australia, Pakistan, India and Hong Kong. In 1985, Iceland became the first country to enforce graphic warnings on cigarette packaging. At the end of December 2010, new regulations in Canada increased the size of tobacco warnings to cover three-quarters of cigarette packaging. As of November 2010, 39 countries have adopted similar legislation. In February 2011, the Canadian government passed regulations requiring cigarette packaging to contain 12 new images to cover three quarters of the outside panel and eight new health messages on the inside panel with full color. As of April 2011, Australian regulations require all packaging to use a bland olive green that researchers determined to be the least attractive color, with 75% coverage on the front of the pack and all of the back consisting of graphic health warnings.

Sources: en.wikipedia.org

Notes from published material

Ribonucleic acid (RNA) is a polymeric molecule that is essential for most biological functions, either by performing the function itself (non-coding RNA) or by forming a template for the production of proteins (messenger RNA). RNA and deoxyribonucleic acid (DNA) are nucleic acids. The nucleic acids constitute one of the four major macromolecules essential for all known forms of life. RNA is assembled as a chain of nucleotides. Cellular organisms use messenger RNA (mRNA) to convey genetic information (using the nitrogenous bases of guanine, uracil, adenine, and cytosine, denoted by the letters G, U, A, and C) that directs synthesis of specific proteins. Many viruses encode their genetic information using an RNA genome. Some RNA molecules play an active role within cells by catalyzing biological reactions, controlling gene expression, or sensing and communicating responses to cellular signals. One of these active processes is protein synthesis, a universal function in which RNA molecules direct the synthesis of proteins on ribosomes. This process uses transfer RNA (tRNA) molecules to deliver amino acids to the ribosome, where ribosomal RNA (rRNA) then links amino acids together to form coded proteins.

The E3 subunit, called the Dihydrolipoyl dehydrogenase enzyme, is characterized as a homodimer protein wherein two cysteine residues, engaged in disulfide bonding, and the FAD cofactor in the active site facilitate its main purpose as an oxidizing catalyst. One example of E3 structure, found in Pseudomonas putida, is formed such that each individual homodimer subunit contains two binding domains responsible for FAD binding and NAD binding, as well as a central domain and an interface domain.

== See also == RO5166017 – TAAR1 partial or full agonist RO5203648 – TAAR1 partial agonist RO5256390 – TAAR1 partial or full agonist RO5263397 – TAAR1 partial agonist EPPTB – TAAR1 antagonist/inverse agonist

Sources: en.wikipedia.org

Further detail

Due to its extremely long half-life, 209Bi can be treated as non-radioactive for nearly all applications. It is much less radioactive than human flesh, so it poses no real radiation hazard. Though 209Bi holds the half-life record for alpha decay, it does not have the longest known half-life of any nuclide; this distinction belongs to tellurium-128 (128Te) with a half-life estimated at 7.7×1024 years by double beta decay. The half-life of 209Bi was confirmed in 2012 by an Italian team in Gran Sasso who reported (2.01±0.08)×1019 years. They also reported an even longer partial half-life for alpha decay of 209Bi to the first excited state of 205Tl (at 204 keV), estimated at 1.66×1021 years. Even though this value is shorter than the half-life of 128Te, both alpha decays of 209Bi hold the record of the thinnest natural line widths of any measurable physical excitation, estimated respectively at ΔΕ ≈ 5.5×10−43 eV and ΔΕ ≈ 1.3×10−44 eV in application of the uncertainty principle

== Chemistry == Metformin hydrochloride (1,1-dimethylbiguanide hydrochloride) is freely soluble in water, slightly soluble in ethanol, but almost insoluble in acetone, ether, or chloroform. The pKa of metformin is 12.4. The usual synthesis of metformin, originally described in 1922, involves the one-pot reaction of a heated solution of dimethylamine hydrochloride and 2-cyanoguanidine.

The C-terminus (also known as the carboxyl-terminus, carboxy-terminus, C-terminal tail, carboxy tail, C-terminal end, or COOH-terminus) is the end of an amino acid chain (protein or polypeptide), terminated by a free carboxyl group (-COOH). When the protein is translated from messenger RNA, it is created from N-terminus to C-terminus. The convention for writing peptide sequences is to put the C-terminal end on the right and write the sequence from N- to C-terminus.

Sources: en.wikipedia.org

Frequently asked questions